Genscript Biotech
Genscript Biotech Corporation, commonly referred to as Genscript, is a leading biotechnology company headquartered in the United States. Founded in 2002, Genscript has established itself as a pioneer in the fields of gene synthesis, peptide synthesis, and antibody development, serving a diverse range of industries including pharmaceuticals, academia, and diagnostics. With major operational regions across North America, Europe, and Asia, Genscript offers a comprehensive suite of services that includes custom gene and protein production, CRISPR gene editing, and molecular biology tools. The company is renowned for its innovative approach and high-quality products, which have positioned it as a trusted partner in the global biotech landscape. Genscript's commitment to advancing scientific research has led to numerous accolades, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Genscript Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech's score of 34 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genscript Biotech's reported carbon emissions
In 2023, Genscript Biotech reported significant carbon emissions, totalling approximately 48821780 kg CO2e for Scope 1 and about 85858740 kg CO2e for Scope 2. Additionally, their Scope 3 emissions reached approximately 314658760 kg CO2e, bringing the total emissions from all scopes to about 97949660 kg CO2e for Scope 1 and 2 combined. In 2024, the company’s emissions showed a slight decrease in Scope 1, with approximately 39376800 kg CO2e, while Scope 2 emissions increased to about 114034820 kg CO2e. Scope 3 emissions also rose to approximately 387589810 kg CO2e, indicating a growing carbon footprint across their operations. Despite these figures, Genscript Biotech has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon emissions. The absence of documented reduction strategies suggests a need for enhanced climate commitments within the biotechnology sector, particularly as companies face increasing scrutiny regarding their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 1,752,700 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,782,800 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
